Here's why Vinay Rajani recommends buying Ajanta Pharma, TTK Prestige

The technical analyst also recommends to hold Nifty longs with a stop at 16,300; on the upside, he expects resistance for the NSE benchmark around 16,800.

NSE, national stock exchange, nifty50
Vinay Rajani Mumbai
2 min read Last Updated : Jul 27 2022 | 7:46 AM IST
The Nifty has been correcting for the last two trading sessions. The Nifty has entered in the gap zone which was created on July 20, 2022 between 15,359 and 16,490. This gap zone could act as a short-term support for the Nifty.

Positional Trend of the Nifty is bullish as it has maintained higher top and higher bottom formation on the daily chart.

Considering the positional up trend, we believe that dips should be utilized to initiate fresh longs. Stop loss for longs should be kept at 16,300. Resistances for Nifty are seen at 16,800 and 17,422. 

TTK Prestige
BUY
Buy range: Rs 888 - 860
Targets: Rs 950, Rs 980
Stop Loss: Rs 850

Last week, the stock broke out from last five month's narrow price consolidation. The price breakout was accompanied with rising volumes.

For the last five trading sessions, the stock price has been consolidating with lower volumes. Further, the Stock is placed above its 50 and 200 days EMA, which indicates bullish trend for medium term.

The stock can be bought in two tranches one at CMP and second at Rs 860, for targets of Rs 950 and Rs 980, keeping a Stop loss at Rs 850. 

Ajanta Pharma
BUY
Buy Range: Rs 1,275 - 1,235
Targets: Rs 1,345, Rs 1,390
Stop Loss: Rs 1,219

On July 19, 2022, the stock surpassed the crucial resistance of its 200 days EMA with jump in volumes. The stock price also broke out from the bullish inverted head and shoulder pattern, last week.

The stock has recently witnessed throwback towards the previous breakout level, which can be considered as a buying opportunity.

The stock can be bought in two tranches one at CMP and second at Rs 1,235, for the targets of Rs 1,345 and Rs 1,390, keeping a stop loss at Rs 1,219.

(Vinay Rajani, Senior Technical and Derivative Research Analyst at HDFC securities. Views expressed are personal).
 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Market trendsMarket technicalsTTK Prestige Ajanta PharmaStocks to buystocks technical analysistechnical chartsStock RecommendationsNifty Outlook

Next Story